Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System
- 1 June 2016
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 67 (6), 1181-1188
- https://doi.org/10.1161/hypertensionaha.116.07363
Abstract
Little is known about the frequency and patterns of hyperkalemia in clinical settings. We evaluated the association between baseline antihypertensive medications that may affect potassium levels (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, loop/thiazide diuretics, and potassium-sparing diuretics) and hyperkalemia, defined by potassium >5 mEq/L and >5.5 mEq/L, over a 3-year time period in 194 456 outpatients in the Geisinger Health System, as well as actions taken after an episode of hyperkalemia. The proportions of patients with 0, 5 mEq/L and >5.5 mEq/L occurred in 10.8% and 2.3% of all patients over the 3-year period; among patients with ≥4 measurements per year, corresponding values were 39.4% and 14.6%. Most cases of hyperkalemia occurred only once during follow-up. The antihypertensive medication class most strongly associated with hyperkalemia was angiotensin-converting enzyme inhibitors. Among patients with a measurement of potassium >5.5 mEq/L, only 24% were seen by a nephrologist and 5.2% were seen by a dietician during the 3-year period. Short-term actions after a potassium measurement >5.5 mEq/L included emergency room visit (3.1% within 7 days), remeasurement of potassium (44.3% with 14 days), and change in a potassium-altering medication (26.4% within 60 days). The most common medication changes were discontinuation/dose reduction of an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or potassium-sparing diuretic, which occurred in 29.1% and 49.6% of people taking these medications, respectively. In conclusion, hyperkalemia is common. Future research may enable optimal renin–angiotensin–aldosterone system inhibitor use with improved management of hyperkalemia.Keywords
This publication has 21 references indexed in Scilit:
- Predictors of Hyperkalemia and Death in Patients With Cardiac and Renal DiseaseThe American Journal of Cardiology, 2012
- Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialHypertension, 2012
- Underuse of ACE inhibitors and angiotensin II receptor blockers among patients with diabetic nephropathy in TaiwanHealth Policy, 2011
- Management of High Blood Pressure in BlacksHypertension, 2010
- The Frequency of Hyperkalemia and Its Significance in Chronic Kidney DiseaseArchives of Internal Medicine, 2009
- Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockersPharmacoepidemiology and Drug Safety, 2006
- Underuse of ACE Inhibitors and Angiotensin II Receptor Blockers in Elderly Patients With DiabetesAmerican Journal of Kidney Diseases, 2005
- The Adequacy of Laboratory Monitoring in Patients Treated With Spironolactone for Congestive Heart FailureJournal of the American College of Cardiology, 2005
- National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic DysfunctionCirculation, 2004
- Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)The Lancet, 1997